Abstract
The term retrovirus is used to denote a class of animal and human viruses that employ a special DNA polymerase (reverse transcriptase) to catalyze the conversion of genomic RNA to DNA in the process of viral replication. These viruses are interesting in that a crucial step in their replication is the reverse transcription of viral RNA to produce linear, double-stranded (minus strand and plus strand) proviral DNA. In this process the termini of the RNA genome are duplicated to yield structures in the DNA called long-terminal repeats (LTRs). The viral genome is expressed from proviral DNA (the minus strand of DNA), which has enhancer/promoter and polyadenylation signals in the LTRs.
Keywords
- Human Immunodeficiency Virus
- Human Immunodeficiency Virus Replication
- Minus Strand
- Human Immunodeficiency Virus Reverse Transcriptase
- Antiviral Chemotherapy
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Daughet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, Rozenbaum W, Montagnier L (1983) Isolation of a T cell lymphotropic virus from a patient at risk for acquired immunodeficiency syndrome ( AIDS ). Science 220: 868–871
Popovic M, Sarngadharan MG, Read E, Gallo RC (1984) Detection, isolation, and continuous production of cytopathic retrovirus ( HTLV-III) from patients with AIDS and pre-AIDS. Science 224: 497–500
Miller R (1988) Human immunodeficiency virus may encode a novel protein on the genomic DNA plus strand. Science 239: 1420–1422
Mitsuya H, Broder S (1987) Strategies of antiviral therapy in AIDS. Nature 325: 773–778
Mitsuya H, Broder S (1986) Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy associated virus (HTLV-III/LAV) by 2’,3’-dideoxynucleosides. Proc Natl Acad Sci USA 83: 1911–1915
Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Lehrman SN, Gallo RC, Bolognesi D, Barry DW, Broder S (1985) 3’-Azido-3’-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy associated virus in vitro. Proc Natl Acad Sci USA 82: 7096–7100
Yarchoan R, Klecker RW, Weinhold KJ, Markham PD, Lyerly HK, Durack DT, Gelmann E, Lehrman SN, Blum RM, Barry DW, Shearer GM, Fischi MA, Mitsuya H, Gallo RC, Collins JM, Bolognesi DP, Myers CE, Broder S (1986) Administration of 3’-azido-3’-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet i: 575–580
Fischl M, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Allan JD, Mildvan D, Schooley RT, Jackson GG, Durack DT, King D, AZT Collaborative Working Group (1987) The efficacy of 3’-azido-3’deoxythymidine (azidothymidine) in the treatment of patients with AIDS and AIDS-related complex: A double-blind placebo-controlled trial. New Engl J Med 317: 185–191
Gottlieb MS, Schroff R, Schanker HM, Weisman JD, Fan PT, Wolf RA, Saxon A (1981) Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men. Evidence of a new acquired cellular immunodeficiency. New Engl J Med 305: 1425–1431
Snider WD, Simpson DM, Nielsen S, Gold JWM, Metroka CE, Posner JB (1983) Neurological complications of acquired immune deficiency syndrome: Analysis of 50 patients. Ann Neurol 14: 403–418
Shaw GM, Harper ME, Epstein LG, Gajdusek DC, Price RW, Navia BA, Petito CK, O’Hara CJ, Groopman JE, Cho ES, Oleske JM, Wong-Staal F, Gallo RC (1985) HTLV-III infection in brains of children and adults with AIDS encephalopathy. Science 227: 177–182
Yarchoan R, Berg G, Brouwers P, Spitzer AR, Fischl MA, Thomas RV, Schmidt P, Safai B, Perno CF, Myers CE, Broder S (1987) Preliminary observation of the response of HTLV-III/LAV-associated neurological disease to the administration of 3’-azido-3’-deoxythymidine. Lancet i: 132–135
Mitsuya H, Matsukura M, Broder S (1987) Rapid in vitro systems for assessing activity of agents against HTLV-III/LAV. In Broder S (ed) AIDS: Modern Concepts and Therapeutic Challenges. Marcel Dekker, New York, pp 303–333
Baltimore D (1970) Viral RNA-dependent DNA polymerase. Nature 226: 1209–1211
Temin HM, Mizutani S (1970) RNA-dependent DNA polymerase in virions of Rous sarcoma virus. Nature 226: 1211–1213
Strebel K, Daugherty D, Clouse K, Cohen D, Folks T, Martin MA (1987) The HIV ‘A’ (sor) gene product is essential for virus infectivity. Nature 328: 728–730
Guy B, Kieny MP, Riviere Y, Peuch CL, Dott K, Girard M, Montagnier L, Lecocq JP (1987) HIV F/3’-orf encodes a phosphorylated GTP-binding protein resembling an oncogene product. Nature 330: 266–269
Smith DH, Byrn RA, Marsters SA, Gregory T, Groopman JE, Capon DJ (1987) Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. Science 228: 1704–1707
Fisher AG, Ratner L, Mitsuya H, Marselle LM, Harper ME, Broder S, Gallo RC, Wong-Staal F (1986) Infectious mutants of HTLV-III with changes in the 3’-orf region and markedly reduced cytopathic effects. Science 233: 655–659
Matsushita S, Robert-Guroff M, Trepel J, Cossman J, Mitsuya H, Broder S (1986) Human monoclonal antibody directed against an envelope glycoprotein of human T-cell leukemia virus type I. Proc Natl Acad Sci USA 93: 2672–2676
Nabel G, Rice S, Knipe D, Baltimore D (1988) Alternative mechanisms for activation of human immunodeficiency virus enhancer in T cells. Science 239: 1299–1301
Felber B, Pavlakis G (1988) A quantitative bioassay for HIV-I based on transactivation. Science 238: 184–187
Sodroski J, Rosen C, Wong-Staal F, Salahuddin SZ, Popovic M, Arya S, Gallo RC (1985) Transacting transcriptional regulation of human T-cell leukemia virus type III long terminal repeat. Science 227: 171–173
Sodroski J, Goh WC, Rosen C, Dayton A, Terwilliger E, Haseltine WA (1986) A second post-transcriptional transactivator gene required for HTLV-III replication. Nature 321: 412–417
Feinberg MB, Jarrett RF, Aldovini A, Gallo RC, Wong-Staal F (1986) HTLV-III expression and production involve complex regulation at the level of splicing and translation of viral RNA. Cell 46: 807–817
McCormick JB, Getchell JP, Mitchell SW, Hicks DR (1984) Ribavirin suppresses replication of lymphadenopathy-associated virus in culture of human adult lymphocytes. Lancet ii: 1367–1369
Matsukura M, Shinozuka K, Zon G, Mitsuya H, Reitz M, Cohen JS, Broder S (1987) Phosphorothioate analogs of ologodeoxynucleotides: Inhibition of replication and cytopathic effects of human immunodeficiency virus. Proc Natl Acad Sci USA 84: 7706–7710
Gruters RA, Neefjes JJ, Tersmette M, Goede RY, Tulp A, Huisman HG, Miedema F, Ploegh HL (1987) Interference with HIV-induced syncytium formation and viral infectivity by inhibitors of trimming glucosidase. Nature 330: 74–77
Montefiori DC, Mitchell WM (1987) Antiviral activity of mismatched double-stranded RNA against human immunodeficiency virus in vitro. Proc Natl Acad Sci USA 84: 2985–2989
Baba M, Pauwels R, Herdewijn P, De Clercq E, Desmyter J, Vandeputte M (1987) Both 2’-3’-dideoxythymidine and its 2’-3’-unsaturated derivative (2’-3’-dideoxythumidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. Biochem Biophys Res Commun 142: 128–134
Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groompan JE, Mildvan D, Hirsch MS, Jackson GG, Durack DT, Lehrman SN, AZT Collaborative Working Group (1987) The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. New Engl J Med 317: 192–197
Yarchoan R, Perno CF, Thomas RV, Klecker RW, Allain JP, Willis RJ, McAtee N, Fischl MA, Dubinsky R, McNeely MC, Mitsuya H, Pluda JM, Lawley TJ, Leuther M, Safai B, Collins JM, Meyers CE, Broder S (1988) Phase I studies of 2’-3’-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with Zidovudine (AZT). Lancet i: 76–81
Mitsuya H, Jarrett RF, Matsukura M, DiMarzo Veronese F, DeVico AL, Sarngadharan MG, Johns DG, Reitz MS, Broder S (1987) Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2’-3’-dideoxynucleosides in vitro. Proc Natl Acad Sci USA 84: 2033–2037
Dahlberg JE, Mitsuya H, Broder S, Blam SB, Aaronson SA (1987) Broad spectrum anti-retroviral activity of 2’-3’-dideoxynucleosides. Proc Natl Acad Sci USA 84: 2469–2473
Larder BA, Purifoy JM, Powell KL, Darby G (1987) Site-specific mutagenesis of AIDS virus reverse trnascriptase. Nature 327: 716–717
Balzarini J, Pauwells R, Baba M, Herdewijn P, de Clercq E, Broder S, Johns DG (1988) The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3 ’-azido-2’-3’-dideoxythymidine and 2’-3’-dideoxycytidine are highly dependent on the cell species. Biochem Pharm 37: 897–903
Ostertag W, Roesler G, Krieg CJ, Kind J, Cole T, Crozier T, Gaedicke G, Steinheider G, Kluge N, Dube S (1974) Induction of endogenous virus and of thymidine kinase by bromodeoxyuridine in cell cultures transformed by Friend virus. Proc Natl Acad Sci USA 71: 4980–4985
De Wolfe F, Lange JMA, Goudsmit J, Cload P, De Gans J, Schellekens PTH (1988) Effect of Zidovudine on serum human immunodeficiency virus antigen levels in symptom-free subjects. Lancet 1: 373–376
Moss A, Bacchetti P, Osmond D, Krampf W, Chaisson R, Stites D, Wilber J, Allain J, Carlson J (1988) Seropositivity for HIV and development of AIDS or AIDS-related condition: Three year follow-up of the San Francisco General Hospital cohort. Br Med J, 745–750
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer-Verlag New York Inc.
About this chapter
Cite this chapter
Broder, S. (1989). HIV: Antiviral Chemotherapy. In: Notkins, A.L., Oldstone, M.B.A. (eds) Concepts in Viral Pathogenesis III. Springer, New York, NY. https://doi.org/10.1007/978-1-4613-8890-6_40
Download citation
DOI: https://doi.org/10.1007/978-1-4613-8890-6_40
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4613-8892-0
Online ISBN: 978-1-4613-8890-6
eBook Packages: Springer Book Archive